Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib.
Yan-Ou Yang, Yunlan Fang, Phillip Wang...
https://pubmed.ncbi.nlm.nih.gov/41360500/Actively Recruiting
Led by Incyte Corporation · Updated on 2026-10-22
98
Participants Needed
24
Research Sites
285 weeks
Total Duration
Researchers are evaluating the efficacy, safety, and tolerability of a drug called INCB000928 in people diagnosed with fibrodysplasia ossificans progressiva FOP, a rare condition. This Phase 2, randomized, double-blind, placebo-controlled trial aims to understand how well INCB000928 works and its pharmacokinetics in different age groups with FOP. The study is sponsored by Incyte Corporation and focuses on treatment outcomes over several years. Participants are divided into three age cohorts 12 years and older, 6 to under 12 years, and 2 to under 12 years after safety review. They receive either INCB000928 or a placebo orally once daily for 24 weeks during the double-blind period. After completing this period, participants may continue in an open-label extension phase lasting an additional 292 weeks, where all receive INCB000928. During the study, participants will undergo low-dose whole-body CT scans excluding the head to monitor new heterotopic ossification lesions. Researchers will measure the number and volume of new lesions and record any new flare-ups. Pharmacokinetics of the drug will be assessed at multiple time points. Safety is closely monitored throughout, including adverse events, with total participation potentially lasting over six years.
CONDITIONS
To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva
I
Incyte Corporation Call Center (US)
I
Incyte Corporation Call Center (ex-US)
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Incyte Corporation
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | INCB000928 (investigational) | Placebo | Palovarotene (standard care context) |
|---|---|---|---|
| What it is | An investigational oral drug taken once daily targeting FOP to prevent new heterotopic ossification lesions. | An inert oral daily placebo used as a control arm. | An approved oral medication used off‑label in FOP to reduce formation of new heterotopic ossification. |
| Role in trial | Experimental therapy administered in three age‑based cohorts. | Control comparator administered orally once daily across cohorts. | Not part of the trial; included for external context. |
| Primary use | Test whether INCB000928 reduces new HO lesions compared with placebo by Week 24. | Serve as a comparison to evaluate INCB000928 effect on new HO lesion formation. | Used clinically to slow or reduce new HO formation in FOP patients. |
| How it is given or performed | Orally once daily. | Orally once daily. | Orally as indicated in clinical practice. |
| Evidence status | Currently under investigation; no published results yet. | Serves as control; no therapeutic effect on HO formation expected. | Has evidence supporting reduction in new HO formation from guideline consensus. |
| Important limitations | No efficacy or safety results yet; dose‑cohort design may limit direct age comparisons. | Placebo control may not reflect best available care context since palovarotene is used off‑label in practice. | Use in FOP is off‑label and not evaluated in randomized trials versus INCB000928 yet. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 24 weeks
Participants receive either INCB000928 or placebo orally once daily for 24 weeks without knowing which they are taking.
Regular visits as defined in the protocol
Duration - 292 weeks
Participants who finish the double-blind period continue taking INCB000928 once daily for up to 292 additional weeks.
Visits for ongoing assessments and monitoring
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Yan-Ou Yang, Yunlan Fang, Phillip Wang...
https://pubmed.ncbi.nlm.nih.gov/41360500/Incyte Corporation
Lead Sponsor